Abstract: Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example.

Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: The present invention is directed to methods and compositions that provide therapy for at least one medical condition that directly or indirectly affects cardiac muscle cells (also known as cardiomyocytes) in a mammalian individual, including humans, dogs, cats, horse pigs, and so forth. The medical condition may be of any kind, including a cardiac condition such as heart failure, cardiomyopathy, myocardial infarction, and so forth. The medical condition may have a cardiac condition as its primary symptom or cause or it may be a secondary symptom or cause. The individual may be male or female and may be of any age.

Abstract: A patient monitoring system is configured to monitor oxygen saturation and/or oxygenation of a patient's blood. The system is configured to re-oxygenate the patient in response to a determination that the patient's oxygen saturation and/or oxygenation has fallen below a threshold (e.g., if the patient is experiencing hypoxemia). A re-oxygenation routine may include an initial step of rapidly oxygenating the patient, followed by a reduction of oxygenation to make the oxygenation process more gradual. For instance, after the initial step of rapid oxygenation, the patient may be oxygenated with oxygen at an atmospheric level. The system may dynamically adjust the ratio of delivered oxygen versus delivered air, the duration of oxygenation, and the incidence of oxygenation. The system may also adjust the automated delivery of one or more drugs to the patient based on the patient's condition and/or the state of re-oxygenation.

Abstract: A transition monitor receives data from a variety of sensors that provide data indicative of the level of sedation of a patient, such as a bispectral index monitor, automated responsiveness monitor, pulse oximeter, or other device. As data is received from a sensor device, the transition monitor will apply a weighting calculation and algorithm to the received value in order to determine a weighted value for the received data. The weighted value is used, along with prior values, to determine a sedated patient's position within a continuum of sedation levels, such as minimal sedation, moderate sedation, or deep sedation. When a newly received value triggers a transition from one sedation level to a next sedation level, one or more thresholds, safeguards, or drug delivery configurations may be modified to adapt to the change within the sedation continuum.

Abstract: An oral-nasal cannula receives exhaled gases from the nose and mouth of a patient. The exhaled gases are transported to variable flow valves that can variably restrict the flow of the gases through the valves upon software generated signals. The exhaled gases pass through the variable flow valves and mix so that they can be measured by a single sensor such as a sensor of a capnometer. Based upon information gathered by the capnometer, the variable valves can be adjusted in real-time according to a software method in order to identify a variable valve flow configuration that maximizes the amount of CO2 received and measured by the capnometer. In this manner, the software can adapt a single capnometer to measure exhaled gases regardless of whether a patient breathes primarily through their nose or mouth or some proportion of the two.

Abstract: Patient demographics gathered from a variety of sources are used to create one or more cumulative risk factors that is used to configure a set of initial drug delivery rules controlling factors such as dosing limits, lockouts, alarm thresholds, and informational displays. These initial drug delivery rules may then be modified during a procedure according to a pharmacodynamic profile that is created, updated, and maintained in real time based upon one or more sources of feedback, such as sensors providing information on patient responsiveness, patient cardiovascular conditions, patient pain levels, and clinician inputs. As the system proposes new or modified drug delivery conditions based upon demographic information and real time feedback, clinicians may review and accept or refuse the proposed changes.

Abstract: A patient preparing for a medical procedure is fitted with a modular connector device that stores patient data, medical procedure data, and other software. The patient connector can then be connected to other modular devices via wired or wireless means, allowing the other modular devices to access the patient connector storage to immediately identify the patient and determine its role within the medical procedure. The patient connector and each modular device may connect wirelessly to a localized network, allowing each device to communicate with each other or with a network server in order to receive updated information on a patient or medical procedure, or to download and configure new device drivers when two incompatible devices attempt to connect. In such a network, a patient may move seamlessly from room to room or from device to device without time consuming manual configurations.

Abstract: A drug delivery system includes drug containers, a pump assembly, a sensor, and a controller. The drug containers each contain a different predetermined drug co-formulation of predetermined first and second drugs, wherein the first drug has a sedative effect. The sensor is adapted to sense a variable associated with the drug containers and output a different drug co-formulation identification signal associated with each of the drug containers based on the sensed variable. The controller is programmed to identify the drug co-formulation for the drug container operatively connected to the pump assembly from the associated identification signal and to control the pump assembly to deliver the drug co-formulation of the one drug container to the patient during a medical procedure according to a corresponding drug delivery algorithm which is different for each of the drug containers. A method is also disclosed which uses the drug delivery system.

Abstract: The present invention is directed to methods and compositions that provide therapy for at least one medical condition that directly or indirectly affects cardiac muscle cells (also known as cardiomyocytes) in a mammalian individual, including humans, dogs, cats, horse pigs, and so forth. The medical condition may be of any kind, including a cardiac condition such as heart failure, cardiomyopathy, myocardial infarction, and so forth. The medical condition may have a cardiac condition as its primary symptom or cause or it may be a secondary symptom or cause. The individual may be male or female and may be of any age.

Abstract: A method for delivering a sedation drug comprising administering a drug to a patient while requesting the patient to respond to an instruction, monitoring a patient's BIS values, bringing the patient to a level of anesthesia where the patient fails to respond to the request within a predetermined response time, and determining a BIS value that coincides with the level of anesthesia corresponding to the failure to respond.

Abstract: A first drug delivery system includes first and second drug-container holders and first and second pump assemblies. The first (second) holder is adapted to receive a first (second) drug container having a first (a different second) dimensioned shape but not a second (first) drug container having a different second (a first) dimensioned shape. A second drug delivery system includes first and second bar code scanners, first and second drug-container holders, and first and second pump assemblies. The first (second) holder is adapted to receive a first (second) drug container having a dimensioned shape and to orient a positioned first (second) bar code of the first (second) drug container to face the first (second) bar code scanner because of the dimensioned shape. In one application, the first drug is a sedative drug, the second drug is an analgesic drug, and the drugs are used during a conscious sedation medical procedure.

Abstract: A medical system includes a sedation system and a central station in communication with the sedation system. The sedation system includes a monitoring unit and a drug delivery unit. The monitoring unit is operable to monitor at least one physiological parameter of a patient. The drug delivery unit is operable to deliver drugs to the patient based on data from the monitoring unit. The central station is operable to store patient related data and access a plurality of sedation systems. The central station may remotely control drug delivery through sedation systems, remotely provide voice instructions through sedation systems, display video feeds from sedation systems, respond to queries from sedation systems, and/or provide other functionalities. The system may also include an instrument that is operable to perform surgical and/or therapeutic procedures on the patient. The sedation system may provide power to the instrument and/or otherwise communicate with the instrument.

Abstract: A medical system includes a sedation system and a central station in communication with the sedation system. The sedation system includes a monitoring unit and a drug delivery unit. The monitoring unit is operable to monitor at least one physiological parameter of a patient. The drug delivery unit is operable to deliver drugs to the patient based on data from the monitoring unit. The central station is operable to store patient related data and access a plurality of sedation systems. The central station may remotely control drug delivery through sedation systems, remotely provide voice instructions through sedation systems, display video feeds from sedation systems, respond to queries from sedation systems, and/or provide other functionalities. The system may also include an instrument that is operable to perform surgical and/or therapeutic procedures on the patient. The sedation system may provide power to the instrument and/or otherwise communicate with the instrument.

Abstract: A method for delivering intravenous drugs to a patient comprising programming a drug delivery system, including a controller and an infusion pump, with a maintenance rate or a loading dose for a drug and causing the drug delivery system to (a) calculate a loading dose based on the maintenance rate or a maintenance rate based on the loading dose, (b) administer the loading dose of the drug to the patient to rapidly achieve a desired level of effect, and (c) administer the drug at a first maintenance rate to maintain the level of effect.

Abstract: A medical system includes a sedation system and a central station in communication with the sedation system. The sedation system includes a monitoring unit and a drug delivery unit. The monitoring unit is operable to monitor at least one physiological parameter of a patient. The drug delivery unit is operable to deliver drugs to the patient based on data from the monitoring unit. The central station is operable to store patient related data and access a plurality of sedation systems. The central station may remotely control drug delivery through sedation systems, remotely provide voice instructions through sedation systems, display video feeds from sedation systems, respond to queries from sedation systems, and/or provide other functionalities. The system may also include an instrument that is operable to perform surgical and/or therapeutic procedures on the patient. The sedation system may provide power to the instrument and/or otherwise communicate with the instrument.